Phaseline

Companies › Boston Scientific

Boston Scientific: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Cardiovascular.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EkoSonicTM Endovascular System with ultrasound-facilitated thrombolysis
Ultrasound-facilitated catheter-directed thrombolytic delivery
–Phase 4Pulmonary Embolism–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04790370EkoSonicTM Endovascular System with ultrasound-facilitated thrombolysisPhase 4Pulmonary EmbolismCardiovascularJul 2025

From the company's SEC filings

Cash of $609m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Theravance Biopharma Inhibikase Therapeutics Kiniksa Pharmaceuticals International CeleCor Therapeutics MedTrace Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.